PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 19199078-4 2009 We observed that zonisamide attenuated MPTP-induced dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC), and homovanillic acid (HVA) depletion in the striatum and reduced the loss of tyrosine hidroxylase (TH) positive neurons and the increase of glial fibrillary acidic protein (GFAP) positive astrocytes in the striatum and substantia nigra after 5 days. Zonisamide 17-27 tyrosine hydroxylase Mus musculus 180-200 20957419-2 2010 Our Western blot analysis and immunohistochemical study showed that the post-treatment with zonisamide prevented significantly dopaminergic cell damage, the depletion of tyrosine-hydroxylase (TH) protein levels and the proliferation of microglia in the striatum and/or substantia nigra 8 days after MPTP treatment. Zonisamide 92-102 tyrosine hydroxylase Mus musculus 170-190 20957419-2 2010 Our Western blot analysis and immunohistochemical study showed that the post-treatment with zonisamide prevented significantly dopaminergic cell damage, the depletion of tyrosine-hydroxylase (TH) protein levels and the proliferation of microglia in the striatum and/or substantia nigra 8 days after MPTP treatment. Zonisamide 92-102 tyrosine hydroxylase Mus musculus 192-194 20424905-2 2010 Our Western blot analysis and immunohistochemical study showed that the post-treatment with zonisamide prevented significantly dopaminergic cell damage, the depletion of tyrosine-hydroxylase (TH) protein levels and the proliferation of microglia in the striatum and/or substantia nigra 8 days after MPTP treatment. Zonisamide 92-102 tyrosine hydroxylase Mus musculus 170-190 20424905-2 2010 Our Western blot analysis and immunohistochemical study showed that the post-treatment with zonisamide prevented significantly dopaminergic cell damage, the depletion of tyrosine-hydroxylase (TH) protein levels and the proliferation of microglia in the striatum and/or substantia nigra 8 days after MPTP treatment. Zonisamide 92-102 tyrosine hydroxylase Mus musculus 192-194 19199078-4 2009 We observed that zonisamide attenuated MPTP-induced dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC), and homovanillic acid (HVA) depletion in the striatum and reduced the loss of tyrosine hidroxylase (TH) positive neurons and the increase of glial fibrillary acidic protein (GFAP) positive astrocytes in the striatum and substantia nigra after 5 days. Zonisamide 17-27 tyrosine hydroxylase Mus musculus 202-204 19199078-5 2009 Our Western blot analysis study also showed that zonisamide can prevent the decrease of TH protein levels and increase of GFAP protein levels in the striatum 5 days after MPTP treatment. Zonisamide 49-59 tyrosine hydroxylase Mus musculus 88-90 19199078-7 2009 Furthermore, zonisamide produced a significant increase of the TH protein levels in the striatum after 1 day, as compared to vehicle-treated group. Zonisamide 13-23 tyrosine hydroxylase Mus musculus 63-65 19199078-10 2009 Our study also demonstrates that the neuroprotective effect of zonisamide against dopaminergic cell damage may be mediated by the elevation of TH activity on dopaminergic system after MPTP treatment in mice. Zonisamide 63-73 tyrosine hydroxylase Mus musculus 143-145